[1]盛佳钰,李春阳,董梦婷,等.桃红四物汤对乳腺癌内分泌治疗药物引发子宫内膜病变的影响[J].西部中医药,2023,36(07):1-5.[doi:10.12174/j.issn.2096-9600.2023.07.01]
　SHENG Jiayu,LI Chunyang,DONG Mengting,et al.Influence of Taohong Siwu Tang on Endometrial Lesions Caused by Endocrine Therapy Agents for Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2023,36(07):1-5.[doi:10.12174/j.issn.2096-9600.2023.07.01]
点击复制

桃红四物汤对乳腺癌内分泌治疗药物引发子宫内膜病变的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年07期
页码:
1-5
栏目:
出版日期:
2023-07-15

文章信息/Info

Title:
Influence of Taohong Siwu Tang on Endometrial Lesions Caused by Endocrine Therapy Agents for Breast Cancer
作者:
盛佳钰, 李春阳, 董梦婷, 帕提古丽·加帕尔, 李晓菲, 薛晓红, 江科
上海中医药大学附属岳阳中西医结合医院，上海 200437
Author(s):
SHENG Jiayu, LI Chunyang, DONG Mengting, Patiguli· JIAPAER, LI Xiaofei, XUE Xiaohong, JIANG Ke
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
关键词:
乳腺癌; 子宫内膜病变; ER基因; 单核苷酸多态性; 桃红四物汤
Keywords:
breast cancer; endometrial lesions; ER gene; single-nucleotide polymorphism
分类号:
R243
DOI:
10.12174/j.issn.2096-9600.2023.07.01
文献标志码:
A
摘要:
目的观察桃红四物汤防治乳腺癌内分泌治疗药物引发子宫内膜病变的临床疗效及安全性，分析雌激素受体α(estrogen receptor α，ERα)基因rs9340799、rs2234693位点单核苷酸多态性（single nucleotide polymorphisms，SNPs）与子宫内膜厚度的相关性。 方法将164例接受他莫昔芬或托瑞米芬药物治疗＞1年的乳腺癌患者随机分为中药组和对照组各82例，均行SNPs测序，并且给予标准剂量的他莫昔芬或托瑞米芬治疗。中药组同时口服桃红四物汤颗粒剂，对照组口服安慰剂颗粒剂。比较两组患者治疗前后子宫内膜诊刮率、子宫内膜厚度及其与SNPs分型的相关性。 结果治疗后，中药组患者子宫内膜厚度为（5.27±2.11）mm，低于治疗前的（8.34±2.90）mm（P＜0.05）；中药组患者子宫内膜厚度及子宫内膜诊刮率均低于对照组（P＜0.05）。治疗后，中药组ERα基因rs9340799位点的A/G与A/A基因型患者子宫内膜厚度低于治疗前，且低于对照组（P＜0.01）。 结论桃红四物汤具有较好防治乳腺癌内分泌药物引起子宫内膜增厚的作用；桃红四物汤能改善ERα基因rs9340799与rs2234693位点患者的子宫内膜厚度，其中对A/G基因型患者效果最好，且安全性较高。
Abstract:
ObjectiveTo observe clinical effects and the safety of Taohong Siwu Tang in the prevention and treatment of endometrial lesions caused by endocrine therapy agents for breast cancer, and to analyze its connections with single-nucleotide polymorphisms (SNPs) of ERα gene rs9340799 and rs2234693 sites. MethodsAll 164 breast cancer patients who accepted tamoxifen or toremifene medication more than one year were randomized into the herb group and the control group, they performed SNPs sequencing, and all the patients were treated with the standard doses of tamoxifen or toremifene. The herb group took the granules of Taohong Siwu Tang; the control group was given the granule of placebo. To compare endometrial diagnostic curretage rate and endometrial thickness before and after the treatment between both groups, and its connection with SNPs pattern. ResultsAfter the treatment, endometrial thickness of herb group was (5.27±2.11)mm, lower than (8.34±2.90)mm before the treatment (P<0.05); the herb group was lower than the control group in endometrial thickness and endometrial diagnostic curretage rate (P<0.05). After the treatment, A/G and A/A genotype of endometrial thickness of ERα gene rs9340799 site of the herb group was lower than that before the treatment, and lower than that of the control group (P<0.01). ConclusionTaohong Siwu Tang could better prevent and treat endometrial thickening caused by endocrine therapy agents for breast cancer. Taohong Siwu Tang could improve endometrial thickening in the patients with ERα gene rs9340799 and rs2234693 sites, among them, it is most effective and safe for patients with A/G genotype.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(07):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]欧红新.绝经后妇女子宫内膜病变患者宫腔镜诊断分析70例[J].西部中医药,2012,25(08):110.
　OU Hong-xin.Diagnostic Analysis on Hysteroscope of 70 Cases of Postmenopausal Women with Endometrial Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(07):110.
[9]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(07):1.
[10]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(07):7.

备注/Memo

备注/Memo:
盛佳钰（1983—），女，博士学位，副主任医师。研究方向：乳腺癌的中医药防治。国家自然科学基金（82004240，82104952）；上海市卫健委卫生行业临床研究专项（202140172）；上海市科委医学创新研究专项（21Y11923600）；上海中医药大学附属岳阳中西医结合医院院级科研课题（2017YJ10）。
更新日期/Last Update: 2023-07-15